IP Library Granted Patent US 9,434,935
Granted Patent B2
US 9,434,935 · App. 13/792,135 · Granted Sep 6, 2016

Modified caspase polypeptides and uses thereof

Inventors: David Spencer (Houston, TX); Wei-Chun Chang (Houston, TX)
Assignee: BELLICUM PHARMACEUTICALS, INC.
C12N9/6472A61K31/4545
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,434,935
App. No.
13/792,135
Granted
Sep 6, 2016
Kind
B2
Abstract

The technology relates in part to compositions comprising modified Caspase-9 polypeptides, compositions comprising nucleic acids coding for modified Caspase-9 polypeptides, chimeric modified Caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified Caspase-9 protein, with reduced basal activity in the absence of the inducer.

Claims (11)

1. A composition comprising a nucleic acid comprising a nucleotide sequence that encodes a chimeric protein comprising a FKBP multimeric ligand binding region and a modified Caspase-9 polypeptide, wherein the modified Caspase-9 polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 9, and comprises the amino acid substitution N405Q, wherein

a) the chimeric protein has a basal activity less than 50% of the basal activity of a chimeric protein comprising a FKBP multimeric ligand binding region and a Caspase-9 polypeptide lacking the caspase recruitment domain (CARD) and having the amino acid sequence of SEQ ID NO: 9; and

b) Caspase-9 activity is induced upon binding of a ligand to the FKBP multimeric ligand binding region of the chimeric protein.

2. The composition of claim 1 , wherein the modified Caspase-9 polypeptide comprises the amino acid sequence of SEQ ID NO: 26.

3. The composition of claim 1 , wherein the FKBP multimeric ligand binding region comprises a F v′ , F vis amino acid sequence.

4. The composition of claim 1 , wherein the ligand is dimeric.

5. The composition of claim 3 , wherein the ligand is dimeric FK506, or a dimeric FK506-like analog.

6. The composition of claim 5 , wherein the ligand is AP1903 or AP20187.

7. The composition of claim 1 , wherein the basal activity is measured using a secreted alkaline phosphatase (SEAP) reporter-based surrogate killing assay.

8. The composition of claim 1 , wherein the modified Caspase-9 polypeptide further comprises the amino acid substitution D330A.

9. The composition of claim 8 , wherein the modified Caspase-9 polypeptide comprises the amino acid sequence of SEQ ID NO: 28.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2024
From: BELLICUM PHARMACEUTICALS, INC.
To: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 066643/0549 →
RELEASE OF SECURITY INTEREST Recorded Nov 3, 2020
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 054295/0946 →
SECURITY INTEREST Recorded Apr 1, 2020
From: BELLICUM PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 052284/0113 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2013
From: SPENCER, DAVID; CHANG, WEI-CHUN
To: BELLICUM PHARMACEUTICALS, INC.
Reel/Frame 031624/0291 →
Continuity (1)
Related Publication 20140255360A1 · Sep 11, 2014